Journal
CURRENT ISSUES IN MOLECULAR BIOLOGY
Volume 44, Issue 10, Pages 5117-5125Publisher
MDPI
DOI: 10.3390/cimb44100348
Keywords
IDH1; IDH2; glioma; astrocytoma; next generation sequencing
Categories
Ask authors/readers for more resources
Mutations in both IDH1 and IDH2 play an important role in the development of gliomas, but the co-occurrence of IDH1 and IDH2 mutations in the same tumor is rare. This study describes a case of an IDH-mutant astrocytoma with both IDH1 and IDH2 mutations, and the patient remains disease-free after nine and a half years. Interrogation of cancer genomic databases and a systematic review confirm the rarity of the concurrent mutations.
Both IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2) mutations play a vital role in the development of gliomas through disruption of normal cellular metabolic processes. Here we describe a case of a patient with an IDH-mutant astrocytoma, in which both IDH1 and IDH2 mutations were detected within the same tumour. The patient remains disease-free, nine and a half years after her initial diagnosis. Interrogation of cancer genomic databases and a systematic review was undertaken, demonstrating the rarity of the co-occurrence of IDH1 and IDH2 mutations in a variety of cancer types, and in glioma specifically. Due to the favourable outcome observed in this patient, the potential effect of concurrent IDH1 and IDH2 mutations on survival was also investigated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available